Gerresheimer AG

Report azionario XTRA:GXI

Capitalizzazione di mercato: €960.2m

Gerresheimer Crescita futura

Criteri Future verificati 3/6

Gerresheimer prevede che gli utili e i ricavi cresceranno rispettivamente di 98.7% e 4% all'anno. Si prevede che l'EPS crescerà di 98.1% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 7.1% in 3 anni.

Informazioni chiave

98.7%

Tasso di crescita degli utili

98.07%

Tasso di crescita dell'EPS

Life Sciences crescita degli utili21.4%
Tasso di crescita dei ricavi4.0%
Rendimento futuro del capitale proprio7.14%
Copertura analitica

Good

Ultimo aggiornamento03 Sep 2026

Aggiornamenti recenti sulla crescita futura

Recent updates

Aggiornamento narrativa • Sep 03

GXI: Execution Risks Around Portfolio Disposals Will Pressure Shares Further

Gerresheimer’s updated analyst fair value target has moved from €12.50 to €20.00, with analysts pointing to higher price targets at several banks and a shift to more neutral ratings after recent portfolio disposals as key supports for this change. Analyst Commentary Recent research on Gerresheimer points to a more balanced view among analysts, with several moving to mid range ratings and setting price targets between €26.00 and €30.00.
Aggiornamento narrativa • Jul 31

GXI: Reporting Delays And Accounting Concerns Will Restrain Confidence Despite China Expansion

Analysts have lifted their price target for Gerresheimer to about €25.26 from about €23.37, reflecting updated assumptions on future P/E levels after recent rating changes that cited valuation, delayed results and company specific overhangs. Analyst Commentary Recent research on Gerresheimer shows a mix of cautious and more constructive views, with several firms revisiting their ratings and price targets.
Aggiornamento narrativa • Jun 16

GXI: Reporting Delays Accounting Scrutiny And Bormioli Overhang Will Cap Near Term Confidence

Gerresheimer's updated analyst price target has come down to €26.80 from €34.10. Analysts point to delayed results, accounting concerns and ongoing overhangs around Bormioli as key reasons for the reset.
Aggiornamento narrativa • Jun 01

GXI: Reporting Delays And Accounting Concerns Will Pressure Long Term Confidence

Analysts have trimmed their price targets on Gerresheimer, with one cut from €34.10 to €26.80 contributing to a modest reduction in the modelled fair value from €24.40 to about €23.37, as concerns around delayed results, accounting issues, and the Bormioli overhang weigh on sentiment. Analyst Commentary Recent research has shifted toward a more cautious stance on Gerresheimer, with several firms moving to neutral ratings and cutting price targets to around €26.80 from about €34.10.
Aggiornamento narrativa • May 03

GXI: FY25 Warning And Deferred Results Will Drive Further Share Weakness

Analysts have trimmed their average price target for Gerresheimer to about €12.90 from €29, citing reduced short- and mid-term estimates following the recent FY25 warning and slightly softer expectations compared with the low end of the company's FY26 guidance. Analyst Commentary Bearish analysts are flagging a more cautious stance on Gerresheimer, pointing to reduced confidence in near term execution and visibility.
Aggiornamento narrativa • Apr 19

GXI: Reset After FY25 Warning Will Highlight Upside From Cautious FY26 Expectations

Gerresheimer's analyst price target has been revised lower to €44.18 from €45.95 as analysts factor in reduced short and mid term estimates following the recent FY25 warning and expectations that FY26 performance may sit near the low end of company guidance. Analyst Commentary The recent revision of the consensus price target to €44.18 reflects how analysts are resetting expectations after the FY25 warning and a more cautious view on FY26, which some see as closer to the low end of company guidance.
Aggiornamento narrativa • Apr 05

GXI: FY26 Guidance Anchor And Lowered Expectations Will Support Long-Term Confidence

The consensus analyst price target for Gerresheimer has decreased from about €34.17 to €24.40. Analysts cite reduced short- and mid-term estimates following the recent FY25 warning, and their FY26 expectations are now slightly below the low end of company guidance.
Aggiornamento narrativa • Mar 22

GXI: FY25 Warning And Deferred Results Will Pressure Shares Further

Analysts have reduced their price target for Gerresheimer to about €12.50 from around €18.90, citing lower short- and mid-term estimates following the recent FY25 warning and expectations that FY26 outcomes could sit near the low end of company guidance. Analyst Commentary Bearish analysts are signaling a more cautious view on Gerresheimer following the recent FY25 warning, with fresh price targets pointing to a more conservative stance on both earnings power and execution over the next few years.
Aggiornamento narrativa • Mar 07

GXI: Reset After FY25 Warning Will Set Up Future Earnings Reappraisal

Analysts have reduced their price target for Gerresheimer to about €46 from about €52, citing a higher discount rate and lower assumed future P/E, along with updated revenue growth and profit margin assumptions, as well as recent cautious Street research following the FY25 warning. Analyst Commentary The latest Street research has turned more cautious after the FY25 warning, with at least one major broker shifting to a Sell stance and cutting its price target to €12.90 from €29.
Aggiornamento narrativa • Feb 21

GXI: Deferred Results And Softer Outlook Will Keep Shares Fairly Priced

Analysts have adjusted their price target on Gerresheimer to €18.90 from €22.00 as they now apply a slightly higher discount rate, a lower assumed revenue growth rate, a modestly higher profit margin, and a reduced future P/E multiple. What's in the News Gerresheimer issued earnings guidance for 2026, targeting revenues of around €2.3b to €2.4b (company guidance).
Articolo di analisi • Feb 10

Investors Don't See Light At End Of Gerresheimer AG's (ETR:GXI) Tunnel

Gerresheimer AG's ( ETR:GXI ) price-to-sales (or "P/S") ratio of 0.4x might make it look like a buy right now compared...
Aggiornamento narrativa • Feb 06

GXI: Index Inclusion And Higher P/E Assumptions Will Support Long-Term Confidence

Analysts have modestly lifted their price target for Gerresheimer, citing small adjustments to fair value and discount rate assumptions, as well as revised expectations for revenue growth, profit margins and future P/E. What's in the News Gerresheimer AG has been added to the Germany SDAX (Total Return) Index, highlighting its inclusion in this segment of the German equity market (Key Developments).
Aggiornamento narrativa • Jan 23

GXI: Reset Expectations Will Set Up Future Reappraisal Of Earnings Quality

Analysts have trimmed their average price target on Gerresheimer to €30 from €55. The change reflects updated expectations for revenue growth, profit margins and future P/E multiples following recent research reviews.
Aggiornamento narrativa • Jan 09

GXI: Profit Warnings Reset Expectations While Drug Delivery Platform Will Drive Reassessment

Gerresheimer's updated fair value estimate has been cut from about €97.07 to around €51.97 as analysts reset price targets sharply lower, citing reduced earnings visibility, a higher discount rate and increased uncertainty following recent profit warnings and rating downgrades. Analyst Commentary Recent Street research has turned more cautious on Gerresheimer, with several firms lowering price targets and adjusting ratings following profit warnings and reduced visibility on the investment case.
Aggiornamento narrativa • Dec 25

GXI: Profit Warnings And Weak Outlook Will Pressure Shares Further

Gerresheimer's analyst price target has been cut sharply from about EUR 47.50 to EUR 22.00, as analysts factor in lower growth, thinner margins, a higher discount rate, and reduced valuation multiples following multiple target downgrades and rising uncertainty around the investment case. Analyst Commentary Bearish analysts have made a series of aggressive downward revisions to Gerresheimer's valuation, cutting price targets from prior levels as high as EUR 99.30 to a range between EUR 23 and EUR 46.
Aggiornamento narrativa • Dec 11

GXI: Long-Term Sector Demand Will Support Confidence Despite Recent Profit Warnings

Analysts have cut their price target on Gerresheimer sharply, from roughly EUR 35 to about EUR 34. This reflects reduced fair value estimates as they factor in lower visibility on the investment case, successive target downgrades across the Street, and ongoing uncertainty following multiple profit warnings.
Articolo di analisi • Nov 30

These 4 Measures Indicate That Gerresheimer (ETR:GXI) Is Using Debt In A Risky Way

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Aggiornamento narrativa • Nov 27

GXI: Long-Term Sector Demand Will Support Confidence After Recent Leadership Change

Gerresheimer's analyst price targets have been significantly reduced recently, with analysts citing ongoing uncertainties and diminished near-term visibility as key factors for the downward revision. Previous targets exceeded €50, but new values are now in the €23 to €46 range.
Aggiornamento narrativa • Nov 10

GXI: Confidence Will Remain Despite Current Uncertainties And Leadership Transition

Gerresheimer's analyst fair value target has been revised downward from €37.84 to €34.62. This change reflects recent broad cuts in price targets by analysts, who cite low visibility and ongoing uncertainties around the company's outlook.
Articolo di analisi • Nov 02

Lacklustre Performance Is Driving Gerresheimer AG's (ETR:GXI) 27% Price Drop

To the annoyance of some shareholders, Gerresheimer AG ( ETR:GXI ) shares are down a considerable 27% in the last...
Aggiornamento narrativa • Oct 27

Ongoing Uncertainties And Downgrades Will Shape Efficiency Efforts Ahead

Gerresheimer's analyst price target has been significantly reduced from €56.36 to €37.84. Analysts cite heightened uncertainties, reduced growth expectations, and a lack of near-term catalysts as reasons for this more cautious outlook.
Aggiornamento narrativa • Oct 13

New Production Lines In Lohr And Skopje Will Improve Efficiency

Analysts have lowered their price target for Gerresheimer from €63.72 to €56.36. They cite more cautious expectations for revenue growth and profitability going forward.
Aggiornamento narrativa • Sep 23

New Production Lines In Lohr And Skopje Will Improve Efficiency

The downward revision in Gerresheimer’s price target reflects recent declines in both net profit margin and consensus revenue growth forecasts, resulting in a reduced fair value estimate from €66.84 to €63.72. What's in the News Wolf Lehmann appointed as incoming CFO, succeeding Dr. Bernd Metzner; Lehmann brings nearly 30 years of international finance and management experience.
Articolo di analisi • Sep 18

Why We're Not Concerned About Gerresheimer AG's (ETR:GXI) Share Price

When close to half the companies in Germany have price-to-earnings ratios (or "P/E's") below 18x, you may consider...
Articolo di analisi • Jul 31

Here's Why Gerresheimer (ETR:GXI) Is Weighed Down By Its Debt Load

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Articolo di analisi • Jun 18

Positive Sentiment Still Eludes Gerresheimer AG (ETR:GXI) Following 28% Share Price Slump

Unfortunately for some shareholders, the Gerresheimer AG ( ETR:GXI ) share price has dived 28% in the last thirty days...
Articolo di analisi • May 30

Shareholders May Be Wary Of Increasing Gerresheimer AG's (ETR:GXI) CEO Compensation Package

Key Insights Gerresheimer's Annual General Meeting to take place on 5th of June Salary of €1.15m is part of CEO Dietmar...
Articolo di analisi • May 29

Gerresheimer (ETR:GXI) Is Due To Pay A Dividend Of €1.25

Gerresheimer AG ( ETR:GXI ) will pay a dividend of €1.25 on the 10th of June. Based on this payment, the dividend yield...
Articolo di analisi • May 14

Is There Now An Opportunity In Gerresheimer AG (ETR:GXI)?

Gerresheimer AG ( ETR:GXI ), is not the largest company out there, but it led the XTRA gainers with a relatively large...
Articolo di analisi • Apr 24

Gerresheimer (ETR:GXI) Is Due To Pay A Dividend Of €1.25

Gerresheimer AG ( ETR:GXI ) has announced that it will pay a dividend of €1.25 per share on the 10th of June. Based on...
Articolo di analisi • Apr 19

Earnings Troubles May Signal Larger Issues for Gerresheimer (ETR:GXI) Shareholders

Gerresheimer AG's ( ETR:GXI ) recent weak earnings report didn't cause a big stock movement. However, we believe that...
Articolo di analisi • Apr 11

It's Down 32% But Gerresheimer AG (ETR:GXI) Could Be Riskier Than It Looks

Gerresheimer AG ( ETR:GXI ) shares have had a horrible month, losing 32% after a relatively good period beforehand. The...
Articolo di analisi • Apr 10

Gerresheimer (ETR:GXI) Will Pay A Dividend Of €1.25

Gerresheimer AG's ( ETR:GXI ) investors are due to receive a payment of €1.25 per share on 10th of June. This means the...
Articolo di analisi • Mar 05

Gerresheimer (ETR:GXI) Has Announced A Dividend Of €1.25

The board of Gerresheimer AG ( ETR:GXI ) has announced that it will pay a dividend on the 10th of June, with investors...
Articolo di analisi • Feb 25

Why Investors Shouldn't Be Surprised By Gerresheimer AG's (ETR:GXI) 25% Share Price Surge

Gerresheimer AG ( ETR:GXI ) shareholders would be excited to see that the share price has had a great month, posting a...
User avatar
Nuova narrativa • Feb 09

Expansion Into High-Margin Biologics And Devices Indicates Strong Future Prospects

Strategic expansion into high-margin segments like drug delivery systems and ready-to-use vials could enhance revenue and EBITDA margins significantly.

Previsioni di crescita degli utili e dei ricavi

XTRA:GXI - Stime future degli analisti e dati finanziari passati (EUR Millions )
DataRicaviUtiliFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
11/30/20282,48163293588
11/30/20272,43039N/A33810
11/30/20262,3554-5524812
11/30/20252,321-320-471210N/A
8/31/20252,25023-439254N/A
5/31/20252,18863-468239N/A
2/28/20252,09079-549185N/A
11/30/20241,99182-131239N/A
8/31/20242,012114-131256N/A
5/31/20242,002115-54344N/A
2/29/20241,999117-15371N/A
11/30/20231,990116-44294N/A
8/31/20231,974107-27287N/A
5/31/20231,959107-80205N/A
2/28/20231,90497-89171N/A
11/30/20221,81796-38222N/A
8/31/20221,72591-45214N/A
5/31/20221,63482-20225N/A
2/28/20221,566854238N/A
11/30/20211,498846212N/A
8/31/20211,465861203N/A
5/31/20211,43293-13182N/A
2/28/20211,4189462243N/A
11/30/20201,4198948222N/A
8/31/20201,385-2553235N/A
5/31/20201,394-3226208N/A
2/29/20201,388-14-16165N/A
11/30/20191,3928128193N/A
8/31/20191,415207N/A161N/A
5/31/20191,410207N/A183N/A
2/28/20191,386179N/A159N/A
11/30/20181,368129N/A173N/A
8/31/20181,351124N/A184N/A
5/31/20181,329131N/A192N/A
2/28/20181,336137N/A206N/A
11/30/20171,348101N/A219N/A
8/31/20171,33149N/A184N/A
5/31/20171,35053N/A176N/A
2/28/20171,35856N/A190N/A
11/30/20161,37558N/A173N/A
8/31/20161,299118N/A195N/A
5/31/20161,292106N/A201N/A
2/29/20161,30199N/A188N/A
11/30/20151,28396N/A204N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che GXI diventerà redditizio nei prossimi 3 anni, il che è considerato una crescita più rapida del tasso di risparmio ( 2.1% ).

Guadagni vs Mercato: Si prevede che GXI diventerà redditizia nei prossimi 3 anni, il che è considerato una crescita superiore alla media del mercato.

Guadagni ad alta crescita: Si prevede GXI diventerà redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di GXI ( 4% all'anno) crescerà più lentamente rispetto al mercato German ( 6.6% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di GXI ( 4% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di GXI sarà basso tra 3 anni ( 7.1 %).

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/09/15 23:46
Prezzo dell'azione a fine giornata2026/09/15 00:00
Utili2025/11/30
Utili annuali2025/11/30

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.

Scoprite il che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Gerresheimer AG è coperta da 30 analisti. 12 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Gaurav JainBarclays
Jonathon UnwinBarclays
Pallav MittalBarclays